Pharmacokinetic Drug Interactions Between Oral Contraceptives and Second-Generation Anticonvulsants Authors
Review Article Drug Interactions
First Online: 13 September 2012 DOI:
Cite this article as: Wilbur, K. & Ensom, M.H.H. Clin Pharmacokinet (2000) 38: 355. doi:10.2165/00003088-200038040-00004 Abstract
Drug interactions between oral contraceptives (OCs) and traditional anticonvulsants have been well described. However, in the past decade, a number of new anticonvulsants have been developed, as well as modifications made in the composition of the OC preparations themselves. Additionally, anticonvulsants are increasingly employed in the therapy of nonseizure-related disorders, placing more women at risk of potential drug interactions that may lead to contraceptive failure.
Second-generation anticonvulsants include felbamate, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide. Most have been approved for adjunctive management of seizures refractory to therapy with traditional anticonvulsants. On the basis of available study data in women receiving concomitant OC preparations, gabapentin, lamotrigine, tiagabine and vigabatrin may be administered without significant pharmacokinetic interactions that potentially diminish contraceptive efficacy. However, additional or alternative contraceptive measures, including using OCs with higher estrogen content, are recommended when using felbamate, oxcarbazepine and topiramate, as these agents have demonstrated enzyme-inducing activity leading to reduced plasma steroid concentrations. The effects of zonisamide in women receiving OCs have yet to be reported.
It is important to characterise the properties [e.g. substrate and enzyme activity (particularly cytochrome P450 3A4 induction)] of new anticonvulsants and recognise their potential to interfere with OCs. However, a pharmacokinetic interaction does not in itself indicate loss of OC efficacy. Contraceptive failure should be measured by changes in ovarian hormone concentrations, maturation of ovarian follicle(s) or ovulation.
Zachariasen RD. Loss of oral contraceptive efficacy by concurrent antibiotic administration. Women’s Health 1994; 22: 17–6
Canadian Broadcasting Company. The nature of things, controversial and dramatic look at the pill (archive 11 March, 1999) [documentary abstract online]. Available from: URL: http://www.tv.cbc.ca/nature_of_things/ [Accessed 1999 Mar 13].
Neinstein L. Contraception in women with special medical needs. Compr Ther 1998; 24: 229–50
Morris S. Drug interaction between phenytoin and oral contraceptives. Drug Intell Clin Pharm 1984; 18: 135–6
Kenyon IE. Unplanned pregnancy in an epileptic. BMJ 1972; 1: 686–7
Crawford P, Chadwick DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990; 30: 592–6
Coulan CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20: 519–26
Janz D, Schmidt D. Antiepileptic drugs and failure of oral contraceptives [letter]. Lancet 1974; I: 1113
Crawford P, Chadwick D, Cleveland P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986; 33: 23–9
Shenfield GM. Oral contraceptives — are drug interactions of clinical significance? Drug Saf 1993; 9: 21–37
Szoka PR, Edgren RA. Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database. Fertil Steril 1988; 49 Suppl. 5: 31–8S.
D’Arcy PF. Drug interactions with oral contraceptives. Drug Intell Clin Pharm 1986; 20: 353–62
Baciewicz AM. Oral contraceptive drug interactions. Ther Drug Monit 1985; 7: 26–35
Fraser IS, Jansen RPS. Why do inadvertent pregnancies occur in oral contraceptive users? Contraception 1983; 27: 531–5
Back DJ, Breckenridge AM, Crawford FE, et al. Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs 1981; 21 (1): 46–61.
Orme MLE, Back DJ. Drug interactions with oral contraceptive steroids. Pharmacy Int 1980; 1: 38–41
Robertson YR, Johnson ES. Interactions between oral contraceptives and other drugs — a review. Curr Med Res Opin 1976; 3: 647–58
Back DJ, Orme MLE. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990; 18: 472–84
Back DJ, Grimmer SFM, Orme ML, et al. Evaluation Committee on Safety of Medicines yellow card reports on oral contraceptives — drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988; 25: 527–32
Back DJ, Breckendridge AM, Crawford FE. An investigation of the pharmacokinetics of ethinylestradiol in women using radioimmunoassay. Contraception 1979; 20: 263–73
Bolt WH, Kappus H, Bolt HM. Ring A oxidation of 17α-ethinylestradiol in man [abstract]. Horm Metab Res 1974; 6: 432.
Orme M, Back DJ. Oral contraceptive steroids — pharmacological issues of interest to the prescribing physician. Adv Contracept 1991; 7: 325–31
Fotherby K, Akpoviroro JO, Abdel-Rahman HA, et al. Pharmacokinetics of ethanyl estradiol in women from different populations. Contraception 1981; 23: 489–96
Timm Wagner L, Kenreigh CA. Choosing oral contraceptives. Am Druggist 1999; 216: 64–71
Kaplan B. Desogetrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 1995; 29: 736–42
Haukkamaa M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception 1986; 33: 559–65
Oldlind V, Olsson SE. Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with Norplant implants. Contraception 1986; 33: 257–61
Perucca E, Hedges A, Makki KA, et al. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984; 11: 533–9
Tomson T, Svensson J, Hilton-Brown P. Relationship of interindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther Drug Monit 1989; 11: 533–9
Patsalos PN, Duncan JS, Shorvon SD. Effect of removal of individual AED on antipyrine kinetics in patients taking polytherapy. Br J Clin Pharmacol 1988; 26: 253–9
Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210–58
Wright SA, Stevens JC. The human hepatic cytochromes 450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1–21
Levy RH. Cytochrome P450 isoenzymes and antiepileptic drug interactions. Epilepsia 1995; 36 Suppl. 5: S8–13.
Backstrom T, Sodergard R. The influence of antiepileptic drugs on steroid plasma levels and binding during the menstrual cycle [abstract]. Acta Endocrinol 1977; 85 Suppl. 212: 42.
Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39: 1–47
Wermeling DP, Chandler MHH, Sides GD, et al. Dithromycin increases ethinyl estradiol clearance without allowing ovulation. Obstet Gynecol 1995; 86: 78–84
Wooley DE, Timeras PS. Gonad brain relationship, effect of female sex hormone on electroshock convulsion in rat. Endocrinology 1962; 70: 196–209
Logothetis J, Harner R. Electrocorticol activation by estrogens. Arch Neruol 1960; 3: 290–7
Gevorkyan ES, Nazaryan KB, Kostanyan AA. Modifying effect of estradiol and progesterone on epileptic activity of the rat brain. Neurosci Behav Physiol 1989; 19: 412–5
Espir M, Walker Me, Lawson JP. Epilepsy and oral contraception. BMJ 1969; 1: 294–5
Toivakka E. Oral contraception in epileptics [abstract]. Arzneimittelforschung 1967; 17: 1085.
Diamond MP, Greene JW, Thompson JM, et al. Interaction of anticonvulsants and oral contraceptives in epileptic adolescents. Contraception 1985; 31: 623–32
Porter RJ, Cereghino JJ, Gladding GD, et al. Antiepileptic drug development program. Cleve Clin Q 1984; 51: 293–505
Jensen PK. Felbamate in the treatment of refractory partial-onset seizures. Epilepsia 1993; 34 Suppl.: S25–9.
Felbamate Study Group In Lennox-Gastaut syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328: 29–33
Graves NM, Holmes GB, Fuerst RH, et al. Effect of felbamate on phenytoin and carbamazepine concentrations. Epilepsia 1989; 30: 225–9
Schumaker RC, Fantel C, Kelton E, et al. Evaluation of elimination of
14C-felbamate in healthy men. Epilepsia 1990; 31 Suppl.: 21–2.
Saano V, Banfield CR, Reidenberg P, et al. Effects of felbamate on the pharmacokinetics of low-dose combination oral contraceptive. Clin Pharmacol Ther 1995; 58: 523–31
Klosterskov Jensen P, Saano V, Haring P, et al. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992; 33: 1149–52
Eldon MA, Underwood BA, Randinitis EJ, et al. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Neurology 1998; 50: 1146–8
Hengy H, Kolle EU. Determination of gabapentin in plasma and urine by high-performance liquid chromatography and precolumn labeling for ultraviolet detection. J Chromatogr 1985; 341: 473–88
Leppik IE. Role of new and established antiepileptic drugs. Epilepsia 1998; 37 Suppl. 5: 2–6.
Matsuo F. Lamotrigine. Epilepsia 1999; 51 Suppl. 5: 30–6.
Holdich T, Whiteman P, Orme M, et al. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill [abstract]. Epilepsia 1991; 32 Suppl.: 96.
Wagner J, Schmid K. Induction of microsomal enzymes in rat liver by oxcarbazepine, 10, 11-dihydro-10-hydroxy-carbamazepine and carbamazepine. Xenobiotica 1987; 17: 951–6
Larkin JG, McKee PJ, Forrest G, et al Evidence of lack of auto and heteroinduction with the novel anticonvulsant oxcarbazepine in healthy volunteers. Br J Clin Pharmacol 1991; 31: 165–71
Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependant enzyme induction by oxcarbazepine? Eur J Clin Pharmacol 1990; 39: 187–8
Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40: 783–7
Brodie MJ. Tiagabine pharmacology in profile. Epilepsia 1995; 36 Suppl. 6: S7–9.
Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J Pharm Med 1994; 4: 141–50
Herranz JL. Tiagabine — recent findings and recommendations for dosage. Rev Neurol 1998; 27: 101–3
So El, Wolff D, Graves NM, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995; 22: 221–6
Sachdeo RC. Topiramate — clinical profile in epilepsy. Clin Pharmacokinet 1998; 34: 335–46
Glauser TA. Topiramate. Epilepsia 1999; 40 Suppl. 5: S70–80.
Levy RH, Bishop F, Streeter AJ, et al. Explanation and prediction of drug interactions with topiramate using CYP450 inhibition spectrum. Epilepsia 1995; 36 Suppl. 4: 47–51.
Rosenfeld WE, Doose DR, Walker SA, et al. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997; 38: 317–23
Back DJ, Bates M, Bowden A, et al. The interaction of phenobarbital and other antiepileptics with oral contraceptive steroid therapy. Contraception 1980; 22: 495–503
Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889–926
French JA. Vigabatrin. Epilepsia 1999; 40 Suppl. 5: 11–6.
Vigabatrin clinical investigator brochure. Strasbourg: Merrell-Dow Research Institute, 1979.
Perucca E. The clinical pharmacology of new antiepileptic drugs. Pharmacol Res 1993; 28: 89–106
Gotti G, Bartoli A, Marchiselli R, et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 1993; 36: 603–6
Rimmer Em, Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 1989; 27: 275–335
Browne TR, Mattson RH, Penry JK, et al. Vigabatrin for refractory complex partial seizures: multicentre single blind study and long term follow-up. Neurology 1987; 37: 184–9
Bartoli A, Gatti G, Cipolla N, et al. A double-blind, placebocontrolled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Epilepsia 1997; 38 (6): 702–7.
Leppik EL, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993; 14: 165–73
Nakasa H, Komiya M, Ohmori S, et al. Characterization of human liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide. Drug Metab Dispos 1993; 21: 777–81
Nakasa H, Nakamura H, Ono S, et al. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol 1998; 54: 177–83
Sonnen AEH. Oxcarbazepine and oral contraceptives [abstract]. Acta Neurol Scand 1990; 82 Suppl. 133: 37.
Hatcher RA, Stewart R, Trussel J, et al, editors. Contraceptive technology. 15th ed. New York (NY): Irvington Publishers, 1990–1992: 134
Reynolds EH. Early treatment and prognosis of epilepsy. Epilepsia 1987; 28: 97–106
Elwes RDC, Johnson AL, Shorvon SD, et al. The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med 1984; 311: 944–7
Krauss GL, Brandt J, Campbell M. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology 1996; 40: 1534–9
CrossRef Copyright information
© Adis International Limited 2000